# A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

> **NCT03772587** · PHASE2 · COMPLETED · sponsor: **Momenta Pharmaceuticals, Inc.** · enrollment: 68 (actual)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** M281
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03772587
- **Lead sponsor:** Momenta Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-10
- **Primary completion:** 2020-06-25
- **Final completion:** 2020-06-25
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772587, "A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03772587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*